Suppr超能文献

VLA整合素β1、α2和α3亚基在恶性乳腺肿瘤中的低表达。

Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours.

作者信息

Pignatelli M, Hanby A M, Stamp G W

机构信息

Department of Histopathology, Hammersmith Hospital, London, U.K.

出版信息

J Pathol. 1991 Sep;165(1):25-32. doi: 10.1002/path.1711650106.

Abstract

The Very Late Antigens (VLAs) are alpha beta heterodimeric transmembrane proteins mediating cell-substratum as well as cell-cell interactions. Changes in their expression and/or function seem to occur in a number of invasive carcinomas and may at least in part explain their abnormal patterns of growth and differentiation. Using monoclonal antibodies to the beta 1 (DH12, A1A-5), alpha 2 (B1.515) and alpha 3 (E1.56) chains, VLA-2 (alpha 2 beta 1) and VLA-3 (alpha 3 beta 1) were studied on cryostat sections of three fibroadenomas and 43 invasive breast carcinomas (29 ductal, 14 lobular) by the avidin-biotin complex immunoperoxidase technique. In non-neoplastic breast tissue and in fibroadenomas VLA-2 and VLA-3 were expressed by myoepithelial cells and on the basolateral surface of the luminal cells. There was weak or absent expression of alpha 2, alpha 3 and the common beta 1 chain in the majority of invasive carcinomas compared to the adjacent normal breast epithelium and preinvasive (in-situ) carcinomas. In addition, the expression of the alpha 2 chain of VLA-2 was reduced significantly (P less than 0.005) in the poorly differentiated ductal breast carcinomas (Grade III) compared to the well (Grade I) and moderately (Grade II) differentiated ductal tumours. These data give further evidence that loss or down-regulation of VLA-2 and VLA-3 occur relatively frequently in invasive cancers, and, at least in the invasive ductal breast carcinomas. Loss of an extracellular matrix receptor controlling growth and differentiation seems to be one of the abnormalities underlying the progression towards an undifferentiated morphology.

摘要

极晚期抗原(VLAs)是αβ异二聚体跨膜蛋白,介导细胞与基质以及细胞与细胞之间的相互作用。在许多浸润性癌中,它们的表达和/或功能似乎发生了变化,这可能至少部分解释了它们异常的生长和分化模式。使用针对β1(DH12,A1A - 5)、α2(B1.515)和α3(E1.56)链的单克隆抗体,通过抗生物素蛋白 - 生物素复合物免疫过氧化物酶技术,对3个纤维腺瘤和43例浸润性乳腺癌(29例导管癌,14例小叶癌)的冷冻切片进行了VLA - 2(α2β1)和VLA - 3(α3β1)的研究。在非肿瘤性乳腺组织和纤维腺瘤中,VLA - 2和VLA - 3由肌上皮细胞表达,并在管腔细胞的基底外侧表面表达。与相邻的正常乳腺上皮和原位癌相比,大多数浸润性癌中α2、α3和共同的β1链表达较弱或缺失。此外,与高分化(I级)和中分化(II级)导管肿瘤相比,低分化导管乳腺癌(III级)中VLA - 2的α2链表达显著降低(P小于0.005)。这些数据进一步证明,VLA - 2和VLA - 3的缺失或下调在浸润性癌症中相对频繁地发生,至少在浸润性导管乳腺癌中如此。控制生长和分化的细胞外基质受体的缺失似乎是向未分化形态进展的潜在异常之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验